Van Bambeke F, Michot JM, et al. 2005. Quinolones in 2005: an update. Clin Microbiol Infect, 11:256–80. Vedantham V, Lalitha P, et al. 2006. Vitreous and aqueous penetration of orally administered moxiﬂoxacin in humans. Eye, 20:1273–8. Vigamox. 2004. [package insert]. Fort Worth, TX, Alcon Laboratories. Walter K, Tyler ME. 2006. Severe corneal toxicity after topical ﬂuoroqui- nolone therapy: report of two cases. Cornea, 25:855–7. Walter S, Kuchenbecker J, et al. 2007. Concentration of moxiﬂoxacin in serum and human aqueous humor following a single 400 mg oral dose. J Cataract Refract Surg, 33:553–5. Wilhelmus KR. 2003. Evaluation and prediction of ﬂuoroquinolone pharma- codynamics in bacterial keratitis. J Ocul Pharmacol Ther,19:493–9. Wilhelmus KR. 2003. Nontuberculous mycobacterial endophthalmitis. Arch Ophthalmol, 121:1663. Wilhelmus KR, Abshire RL, et al. 2003. Inﬂuence of ﬂuoroquinolone susceptibility on the therapeutic response of ﬂuoroquinolone-treated bacterial keratitis. Arch Ophthalmol, 121:1229–33. Moxiﬂoxacin hydrochloride ophthalmic solution Winthrop KL, Steinberg EB, et al. 2003. Epidemic and sporadic cases of nontuberculous mycobacterial keratitis associated with laser in situ keratomileusis. Am J Ophthalmol, 135:223–4. Wise R. 2003. Maximizing efﬁcacy and reducing the emergence of resis- tance. J Antimicrob Chemother, 51(Suppl 1):7–42. Woodward M, Randleman JB. 2007. Bilateral methicillin-resistant Staphy- lococcus aureus keratitis after photorefractive keratectomy. J Cataract Refract Surg, 33:316–9. Zhanel GG, Ennis K, et al. 2002. A critical review of the ﬂuoroquinolones: focus on respiratory infections. Drugs, 62:13–59. Zhanel GG, Fontaine S, et al. 2006. A review of new ﬂuoroquinolones: focus on their use in respiratory tract infections. Treat Respir Med, 5:437–65. Zhanel GG, Noreddin AM. 2001. Pharmacokinetics and pharmacodynam- ics of the new ﬂuoroquinolones: focus on respiratory infections. Curr Opin Pharmacol, 1:459–63. Clinical Ophthalmology 2008:2(1) 91